

FIG. 1




FIG. 2




FIG. 3

Scheme 2




FIG. 4




FIG. 5




FIG. 6




FIG. 7A






FIG. 7B









FIG. 9A



Treatment	Ab IC50	% no blocking	blocking
huMOV19-NTS#2-compound A	2e-11 M	1e-9 M	1e-9 M
huMOV19-s-SPDB-compound A	6e-11 M	1e-9 M	1e-9 M

FIG. 9B





FIG. 10






FIG. 12A




FIG. 12B




FIG. 12D





FIG. 13

Anti-Tumor Activity (Median Tumor Volume, mm³) of huMOV19NTS#2-Linker1-Compound A Conjugate in SCID Mice Bearing NCI-H2110 Xenografts



Treatment Group	Dose (µg/kg)	T/C (Day 24)	Regressions		Result
			PR	CR	
A Control	-	-	-	-	-
B huMOV19NTS#2-Linker1-Compound A	10	18%	0/6	0/6	Inactive
C huMOV19NTS#2-Linker1-Compound A	25	3%	6/6	0/6	Highly Active
D huMOV19NTS#2-Linker1-Compound A	50	4%	5/6	2/6	Highly Active

FIG. 14




FIG. 15




FIG. 16




FIG. 17

Scheme 4




FIG. 18

Scheme 5




FIG. 19

Scheme 6




FIG. 20




FIG. 21A

Scheme 7





FIG. 21B

huMov19NTS2S3-SeriMab-MayNMA




FIG. 22A




FIG. 22B




FIG. 22C

MOLM-1




FIG. 23




FIG. 24

EOL-1 cells




FIG. 25

Cytotoxicity vs. EOL-1 and Namalwa cells




FIG. 26

FIG. 26A




FIG. 26B




FIG. 26C




FIG. 27




FIG. 28






FIG. 29



huMOV19-SeriMab-D8, 200 µg/kg




FIG. 30




FIG. 31




FIG. 31A

FIG. 31B

2-Step Method